Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PHASE II RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER EFFICACY AND SAFETY STUDY OF TANEZUMAB AS ADD-ON THERAPY TO OPIOID MEDICATION IN PATIENTS WITH PAIN DUE TO BONE METASTASES

NCT00545129 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00545129
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00545129 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PHASE II RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER EFFICACY AND SAFETY STUDY OF TANEZUMAB AS ADD-ON THERAPY TO OPIOID MEDICATION IN PATIENTS WITH PAIN DUE TO BONE METASTASES
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
April 29, 2009
Completion date
February 7, 2012
Enrollment
59 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasm metastasis, palliative care